ADMA BIOLOGICS INCADMA
ASignal's systematic analysis rates ADMA as Bullish.
Reflects the latest available analysis · analyzed Sep 29, 2026
The case on ADMA
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong gross margin (64.70%) indicating pricing power
- High return on equity (41.90%) signaling efficient capital use
- Positive free cash flow ($54.76M) and strong operating cash flow
- Low debt-to-equity ratio (0.50x) reflecting solid financial health
- Current price above 20-day and 50-day moving averages
- MACD above signal line with expanding histogram, confirming uptrend
- Limited news coverage (only 3 sources, all from Yahoo)
- No Reddit mentions, indicating low retail investor interest or visibility
- Revenue growth weak at 2.00% YoY despite strong earnings growth
- Price trading above upper Bollinger Band (10.07) suggesting overextension
See the full verdict on ADMA
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ADMA
Most investors never get a second opinion, let alone several. ASignal runs ADMA past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.